doi:10.3969/j.issn.1673-8640.2015.06.011

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 12

[1]	张淑红,刘红敏,赵洪方.心力衰竭患者血浆 BNP 的水平及其临床意义[J].中国医药指南,2013,11(30):477-478.
[2]	贺岩,李富荣,杜宗孝,等. 血清BNP、hs-CRP、cTnI及UA联合检测对心力衰竭的临床价值[J]. 检验医学,2012,27(8): 647-650.
[3]	邱锡荣,彭冬迪,唐荣,等. 三种心肌标志物检测对心肌梗死及心力衰竭临床诊断的价值[J]. 检验医学,2011,26(12): 814-817.
[4]	应晓. B型钠尿肽在心力衰竭中的临床应用价值[J]. 检验医学,2010,25(4): 317-318.
[5]	廖予婕. cTnI、hs-CRP和BNP在心力衰竭患者治疗前后的变化及其对诊断和预后判断的价值[J]. 检验医学,2010,25(2): 92-95.
[6]	朱笑频,王成刚. NT-proBNP和cTnI联合检测在急诊心力衰竭患者诊治中的应用[J]. 检验医学,2013,28(1): 30-32.
[7]	伍树芝,邓胜,秦伟国,等. 联合检测NT-proBNP、H-FABP和cTnI对老年重症心力衰竭患者的临床价值[J]. 检验医学,2014,29(4): 312-318.
[8]	NDREPEPA G,BRAUN S,MEHILLI J,et al.Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease[J].Cardiology,2008,109(4):249-257.
[9]	DICKSTEIN K,COHEN-SOLAL A,FILIPPATOS G,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM)[J].Eur Heart J,2008,29(19):2388-2442.
[10]	JUG B,SALOBIR BG,VENE N,et al.Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure[J]. Heart Vessels,2009,24(4):271-276.
[11]	NISSEN SE,TUZCU EM, SCHOENHAGEN P,et al.Statin therapy,LDL cholesterol,C-reactive protein and coronary artery disease[J].N Engl J Med,2005,352(1):29-38.
[12]	孙艺英,李长生.充血性心力衰竭辨证分型与血浆BNP、血清CRP相关性研究[J].山东医药,2008,48(13):53-54.

组别	例数	BNP (pg/mL)	hs-CRP (mg/mL)
CHF组	194	534.5±60.8^**	5.4±2.6^*
NYHAⅠ级	38	115.7±54.3	3.1±1.2
NYHAⅡ级	56	334.2±120.4^#	4.3±2.3
NYHAⅢ级	59	630.6±228.5^##△	5.9±2.7
NYHAⅣ级	41	1 058.0±525.7^##△▲	8.2±3.1
正常对照组	60	38.6±8.7	1.4±1.1

组别	例数	BNP (pg/mL)	hs-CRP (mg/mL)
CHF组	194	534.5±60.8^**	5.4±2.6^*
NYHAⅠ级	38	115.7±54.3	3.1±1.2
NYHAⅡ级	56	334.2±120.4^#	4.3±2.3
NYHAⅢ级	59	630.6±228.5^##△	5.9±2.7
NYHAⅣ级	41	1 058.0±525.7^##△▲	8.2±3.1
正常对照组	60	38.6±8.7	1.4±1.1

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 12

Related Articles 15

Recommended Articles

Metrics